Fate Therapeutics vs TScan Therapeutics
FATE and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FATE and TCRX compare
Fate Therapeutics is the larger company, worth 12 times as much as TScan Therapeutics ($122M against $10.2M).
TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −23.4% for Fate Therapeutics).
TScan Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1655% compared with −1941% at Fate Therapeutics.
Fate Therapeutics scores higher on the StockData Score (8 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FATE | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | $122M | $10.2M |
| Share price | $1.02 | $0.151 |
| Change, 1 year | 5.8% | −86.3% |
| Change, 5 years | −98.1% | −98.3% |
| Beta (5Y) | 3.98 | 2.15 |
| Employees | 161 | 142 |
| StockData Score | ||
| Total score | 8 (better) | 4 |
| Valuation score | 3 | 3 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 18.8× | 1.4× (better) |
| P/B | 0.8× | 0.1× (better) |
| FCF yield | −86.4% (better) | −1157% |
| Fair value | $1.34 | $1.36 |
| Margin of safety | 23.8% | 88.9% (better) |
| Growth | ||
| Revenue growth (TTM) | −23.4% | 2.2% (better) |
| Revenue growth, 5Y average | −26.7% | 56.9% (better) |
| Profitability | ||
| Operating margin | −2058% | −1695% (better) |
| Net margin | −1941% | −1655% (better) |
| FCF margin | −1627% (better) | −1666% |
| Return on equity | −60.7% (better) | −95.8% |
| Return on invested capital | −553% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.47 (better) |
| Interest coverage | – | −43.2× |
| Current ratio | 4.85 (better) | 3.37 |
| Altman Z-score | −8.99 | −6.31 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 59.9% | 53.5% |
| Held by insiders | 25.7% | 32.8% |
| Insider net buying, 12 months | −$336K | $146K (better) |
| Short interest, % of float | 11.2% | 4.4% |
Go deeper
- FATE stock overview
- FATE income statement
- FATE valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.